drugset / Trial / NCT01141556

Effects of High-dose Intravenous Selenium (Selenase®) in Adult Patients Subjected to Elective All-cause Heart Surgery

NCT01141556

Phase 3 Completed 410 enrolled University Hospital, Basel, Switzerland
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Selenoenzymes play a major role in protecting cells against lipid peroxidation and they are involved in the inflammatory response regulation. The degree of selenium deficiency correlates with disease severity and the incidence of mortality in critically ill patients. The aim of our study is to evaluate, if high dosis selenium supplementation (loading dose 4000 μg, daily dosage 1000 μg) results in a significant reduction of inflammation-induced organ dysfunction and length of ICU-stay in patients after heart surgery.

Timeline

Start
2010-12
Primary completion
2012-07
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator sodium selenite Unknown 1000 ug Intravenous

Indications

No indication recorded.